W. Schlick (Wien, Austria), P. Mallia (London, United Kingdom)
5-day moxifloxacin versus 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis: a cost-minimization analysis C. Lazzaro, R. Busca (Milan, Italy)
| |
The role of bacterial infection in Indigenous Australians with COPD is different to that seen in developed world populations G. P. Maguire, P. Dasari, D. Gal, M. Nasir, B. J. Currie (Darwin, Australia)
| |
Relation between bronquial colonization and functional impairment in COPD patients. Sensitivity patterns to classical and new antibiotics A. Baloira, C. Vilariño, L. Perez de LLano, M. Campello (Pontevedra, Lugo, Spain)
| |
Lung function in patients with different infecting agents caused acute exacerbation of COPD K. Y. Gashynova (Dniepropetrovsk, Ukraine)
| |
Pulmonary function testing: an useful oracle for predicting the pattern of bacterial pathogens in sputum of patients with acute exacerbation of COPD M. Biagini, M. Naldi, M. Rossi (Arezzo, Siena, Italy)
| |
Impacts on Mycoplasma pneumoniae infection in acute exacerbation of chronic obstructive pulmonary disease H. Lee, Y. Lee, Y. Rhee (Chonju, South Korea)
| |
Most frequent bacterial agents and antimicrobal therapy in patients with different types of acute exacerbation of COPD K. E. Bogatska, K. Y. Gashynova, Y. V. Popovich (Dniepropetrovsk, Ukraine)
| |
Procalcitonin and C-reactive protein levels in infective attacks of COPD A. B. Onaran, E. Kiyan, A. Orhan, E. Turhan, E. Ozturk (Istanbul, Turkey)
| |
Sputum culture results of COPD patients with infective attack G. Okumus, E. Kiyan, A. Turkozu, R. Berkiten, O. Arseven, T. Ece (Istanbul, Turkey)
| |
Influenza antibodies in patients with COPD N. V. Yakovleva, A. N. Kokosov (St Petersberg, Russia)
| |
Does the condition of chronic obstructive pumonary disease (COPD) have a prognostic benefit in patients with community-acquired pneumonia (CAP)? A. de Roux, A. Rano, E. Garcia, M. A. Marcos, I. Aldabo, J. Puig de la Bellacasa, J. Mensa, A. Torres (Barcelona, Spain)
| |
Community-acquired pneumonia (CAP) in chronic obstructive pulmonary disease (COPD) N. Lampron, J. La Forge, J. Plante, M. Simon (Ste-Foy, Canada)
| |
Candidacidal activity of polymorphonuclear granulocytes (PMNs) and Candida hydrolytic enzymes in COPD H. Batura-Gabryel, A. Szczepanik, P. Gabryel, B. Brajer (Poznan, Poland)
| |
The immuneresponse against bacterial antigens is generated in vivo by a mechanical bacterial lysate through a cross-talk between innate and adaptive immunity G. G. Melioli, A. M. C. Machì, G. G. Rossi, E. E. Pallestrini, G. G. Ferlazzo (Genova, Italy)
| |